Table S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma | Synapse
September 16, 2024
Table S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Table S2: Dose reduction, delay, and omission due to AE.